GB001 clinical trials
Also written GB001.
- studies test it
- 4
- open now
- 0
- in phase 3
- 0
- first study started
- 2018
How each study uses GB001 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Development codes
- GB001
- 2
Studies by the year they started
4 studies that test it; most in 2018 (1)
| Year | Studies |
|---|---|
| 2018 | 1 |
| 2019 | 1 |
| 2022 | 1 |
| 2023 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 4 · Other 0
Zhejiang Echon Biopharm Limited (2) · GB001, Inc, a wholly owned subsidiary of Gossamer Bio, Inc. (2)
Studies
Open first, then newest update. How each study uses GB001 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 4
- Safety and Efficacy Study of GB001 Recombinant Peptide Spray in Subjects With Mild Recurrent Aphthous UlcersActive, not recruitingPhase 2Zhejiang Echon Biopharm LimitedNCT06429566Written as GB001 recombinant peptide spray low dose group、high dose group
- Safety,Tolerability,and Pharmacokinetics Profiles of GB001 Recombinant Peptide Spray in Healthy SubjectsActive, not recruitingPhase 1Zhejiang Echon Biopharm LimitedNCT05125211Written as GB001 recombinant peptide spray
- GB001 in Adult Subjects With Moderate to Severe AsthmaCompletedPhase 2GB001, Inc, a wholly owned subsidiary of Gossamer Bio, Inc.NCT03683576Written as GB001
- GB001 in Adult Participants With Chronic RhinosinusitisCompletedPhase 2GB001, Inc, a wholly owned subsidiary of Gossamer Bio, Inc.NCT03956862Written as GB001